NeuroBell

NeuroBell operates in neonatal neuro-monitoring, focusing on portable EEG and automated seizure detection for neonatal intensive care units. Its LUNA system combines a wireless EEG amplifier, a cloud-based portal, AI-supported analysis, real-time alerts, and a neonatal headcap designed for rapid application. This creates a more integrated bedside workflow than standalone EEG hardware or software-only monitoring products. NeuroBell’s announced relationship with Parkview Health and its Fort Wayne office provide evidence of clinical and US-market activity, while investors including Atlantic Bridge, Elkstone Capital Partners, Furthr VC, and Enterprise Ireland give the company support across medtech and early-stage financing. Its differentiation is therefore best understood at the product level: portability, automated neonatal seizure alerts, cloud-enabled remote review, and a workflow aimed at reducing setup complexity for NICU staff.

NeuroBell’s trajectory shows a transition from early product development toward clinical validation and international commercialization. The company was founded in 2022 and received a grant announced on Mar 13, 2023, followed by a $2.1 million seed round announced on Jan 8, 2024 and led by Furthr VC. Its next financing, a $5.5 million venture round announced on Jun 29, 2026, increased disclosed funding to $7.6 million and included six investors, among them Parkview Health and Atlantic Bridge. The financing coincided with the creation of a Fort Wayne office, indicating a shift from an Ireland-based development focus toward US clinical and market-access activity. Reports in July 2026 described the company as nearing launch of its brain-monitor device in Fort Wayne. Product development is centered on LUNA, an AI-powered neonatal EEG monitor designed for bedside seizure detection. The main inflection points are the 2024 seed financing, the 2026 US expansion, and the move toward launch; commercial scale and regulatory progress remain unclear.